Qiagen NV
$ 50.95
-0.55%
06 Feb - close price
- Market Cap 10,499,518,000 USD
- Current Price $ 50.95
- High / Low $ 51.64 / 50.80
- Stock P/E 24.98
- Book Value 18.33
- EPS 2.04
- Next Earning Report -
- Dividend Per Share $0.26
- Dividend Yield 0.51 %
- Next Dividend Date -
- ROA 0.06 %
- ROE 0.12 %
- 52 Week High 57.82
- 52 Week Low 35.53
About
Qiagen NV is a premier provider of sample-to-knowledge solutions that facilitate the transformation of biological materials into vital insights across the life sciences, clinical diagnostics, and pharmaceutical sectors. Headquartered in Venlo, the Netherlands, the company employs advanced genomic and proteomic technologies, offering researchers and healthcare professionals crucial molecular data to drive innovation and enhance patient care. With a commitment to innovation and strategic collaborations, Qiagen is positioned to capitalize on the growing demand for molecular testing and personalized healthcare, reinforcing its integral role in the advancing healthcare landscape.
Analyst Target Price
$54.46
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-04 | 2025-11-04 | 2025-08-05 | 2025-05-07 | 2025-02-05 | 2024-11-06 | 2024-07-30 | 2024-04-28 | 2024-02-05 | 2023-10-30 | 2023-08-08 | 2023-05-02 |
| Reported EPS | 0.62 | 0.64 | 0.63 | 0.58 | 0.64 | 0.62 | 0.6 | 0.5 | 0.6 | 0.56 | 0.57 | 0.57 |
| Estimated EPS | 0.62 | 0.62 | 0.63 | 0.54 | 0.65 | 0.59 | 0.56 | 0.47 | 0.6 | 0.54 | 0.56 | 0.51 |
| Surprise | 0 | 0.02 | 0 | 0.04 | -0.01 | 0.03 | 0.04 | 0.03 | 0 | 0.02 | 0.01 | 0.06 |
| Surprise Percentage | 0% | 3.2258% | 0% | 7.4074% | -1.5385% | 5.0847% | 7.1429% | 6.383% | 0% | 3.7037% | 1.7857% | 11.7647% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Jan 1970 | Jul 2025 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|
| Payment Date | None | 2025-07-10 | None | None |
| Amount | $2.29 | $0.25 | $1.32 | $1.04 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: QGEN
2026-02-07 12:29:16
This article mentions that Qiagen is targeting a 9% growth rate by 2026 for its growth pillars and aims to achieve $2 billion in revenue by 2028. This growth is expected to be driven by new product launches.
2026-02-07 03:32:19
QIAGEN N.V. (NYSE:QGEN) reported strong Q4 and full-year 2025 results, exceeding their financial outlook for both sales and adjusted earnings per share. The company's growth pillars, including Sample technologies, QuantiFERON, QIAstat, QIAcuity, and QIAGEN Digital Insights, achieved significant sales growth and are on track to meet their 2028 targets. QIAGEN also detailed strategic investments, new product launches, and continued capital returns to shareholders, while providing a cautious but optimistic outlook for 2026 amid ongoing macroeconomic uncertainties.
2026-02-06 23:32:19
JP Morgan has increased its price target for Qiagen (QGEN) to $60.00 from $55.00, reiterating an Overweight rating. This upward adjustment reflects a positive outlook from the firm, indicating anticipated growth potential for the company. Other analysts have also adjusted their ratings and price targets for QGEN in recent months, showcasing varied perspectives on its future prospects.
2026-02-06 21:32:19
QIAGEN N.V. has released a voting rights announcement in accordance with Article 40, Section 1 of the WpHG, based on a notification from the AFM dated February 5, 2026. The disclosure details DWS Investment GmbH's indirect holdings in QIAGEN N.V. as of February 3, 2026, showing a capital interest and voting rights of 1.63% and 3.05% respectively. QIAGEN N.V. emphasizes it is not responsible for the accuracy of the provided notification.
2026-02-06 21:32:19
QIAGEN N.V. has released a voting rights announcement according to Article 40, Section 1 of the WpHG. The notification, issued by the AFM, indicates that DWS Investment GmbH has disclosed a notification related to QIAGEN N.V., with a capital interest of 1.63% and voting rights of 3.05%. The transaction date was February 3, 2026.
2026-02-06 16:01:10
Stifel increased its price target for Qiagen NV (NYSE:QGEN) to $50.00 from $45.00 while maintaining a Hold rating, noting the company is currently undervalued according to InvestingPro data. Qiagen's first-quarter guidance was below consensus, but Stifel projects approximately 3% organic growth for FY2026, with acceleration in the second half. The stock's performance is expected to be largely influenced by takeover speculation, despite its "GREAT" financial health and aggressive share buybacks.
